Paper745014
On the mode of action of L-deprenyl in the human central nervous system.
Riederer P and 5 others. J Neural Transm, 1978. Cited by 111 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. On the mode of action of L-deprenyl in the human central nervous system. Papers, record 745014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/745014
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Blood Platelets | Major topic |
| Brain | Major topic |
| Phenethylamines | Major topic |
| Selegiline | Major topic |
| Dose-Response Relationship, Drug | |
| Humans | |
| Mitochondria | |
| Monoamine Oxidase | |
| Substrate Specificity |
Source PubMed
References17
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 1,101,049 | Monoamine oxidase. Its inhibition. | Mod Probl Pharmacopsychiatry | 1975 | https://conductscience.org/library/papers/1101049 | PubMed |
| 2 | 8,682 | Multiple forms of monoamine oxidase: fact and artefact. | Life Sci | 1976 | https://conductscience.org/library/papers/8682 | PubMed |
| 3 | 745,014 | On the mode of action of L-deprenyl in the human central nervous system. | J Neural Transm | 1978 | https://conductscience.org/library/papers/745014 | PubMed |
| 4 | 5,659,776 | Some observations upon a new inhibitor of monoamine oxidase in brain tissue. | Biochem Pharmacol | 1968 | https://conductscience.org/library/papers/5659776 | PubMed |
| 5 | 4,607,554 | Monoamine oxidase in man: enzyme characteristics in platelets, plasma, and other human tissues. | Adv Biochem Psychopharmacol | 1974 | https://conductscience.org/library/papers/4607554 | PubMed |
| 6 | 5,415,111 | Multiple forms of human brain mitochondrial monoamine oxidase. | Nature | 1970 | https://conductscience.org/library/papers/5415111 | PubMed |
| 7 | 1,172,524 | The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. | J Neural Transm | 1975 | https://conductscience.org/library/papers/1172524 | PubMed |
| 8 | 13,971,142 | [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis]. | Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr | 1962 | https://conductscience.org/library/papers/13971142 | PubMed |
| 9 | 71,602 | Deprenyl in Parkinson's disease. | Lancet | 1977 | https://conductscience.org/library/papers/71602 | PubMed |
| 10 | 834,248 | Dopamine is a monoamine oxidase B substrate in man. | Nature | 1977 | https://conductscience.org/library/papers/834248 | PubMed |
| 11 | 65,560 | Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. | Lancet | 1977 | https://conductscience.org/library/papers/65560 | PubMed |
| 12 | 5,054,207 | Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species. | Adv Biochem Psychopharmacol | 1972 | https://conductscience.org/library/papers/5054207 | PubMed |
| 13 | 329,649 | Are there MAO inhibitors specific for dopamine metabolism? | Adv Biochem Psychopharmacol | 1977 | https://conductscience.org/library/papers/329649 | PubMed |
| 14 | 890,205 | Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine. | Br J Pharmacol | 1977 | https://conductscience.org/library/papers/890205 | PubMed |
| 15 | 696,465 | Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies. | Adv Biochem Psychopharmacol | 1978 | https://conductscience.org/library/papers/696465 | PubMed |
| 16 | 13,901,297 | The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. | J Anat | 1962 | https://conductscience.org/library/papers/13901297 | PubMed |
| 17 | 745,019 | Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. | J Neural Transm | 1978 | https://conductscience.org/library/papers/745019 | PubMed |
Cited by30
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 111 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36,964,457 | Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations. | J Neural Transm (Vienna) | 2023 | https://conductscience.org/library/papers/36964457 | PubMed |
| 35,107,654 | A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease. | J Neural Transm (Vienna) | 2022 | https://conductscience.org/library/papers/35107654 | PubMed |
| 34,437,505 | Pharmacological Modulation of Behaviour, Serotonin and Dopamine Levels in Daphnia magna Exposed to the Monoamine Oxidase Inhibitor Deprenyl. | Toxics | 2021 | https://conductscience.org/library/papers/34437505 | PubMed |
| 31,562,557 | Selegiline: a molecule with innovative potential. | J Neural Transm (Vienna) | 2020 | https://conductscience.org/library/papers/31562557 | PubMed |
| 30,108,930 | Design, synthesis and evaluation of indole derivatives as multifunctional agents against Alzheimer's disease. | Medchemcomm | 2018 | https://conductscience.org/library/papers/30108930 | PubMed |
| 29,417,334 | Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease. | J Neural Transm (Vienna) | 2018 | https://conductscience.org/library/papers/29417334 | PubMed |
| 27,065,872 | Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. | Front Pharmacol | 2016 | https://conductscience.org/library/papers/27065872 | PubMed |
| 22,936,314 | Inhibition of bupropion metabolism by selegiline: mechanism-based inactivation of human CYP2B6 and characterization of glutathione and peptide adducts. | Drug Metab Dispos | 2012 | https://conductscience.org/library/papers/22936314 | PubMed |
| 22,110,357 | MAO-inhibitors in Parkinson's Disease. | Exp Neurobiol | 2011 | https://conductscience.org/library/papers/22110357 | PubMed |
| 19,396,396 | Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. | J Neural Transm (Vienna) | 2009 | https://conductscience.org/library/papers/19396396 | PubMed |
| 12,873,156 | Neuroprotective strategies in Parkinson's disease : an update on progress. | CNS Drugs | 2003 | https://conductscience.org/library/papers/12873156 | PubMed |
| 9,704,592 | Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain. | Neurochem Res | 1998 | https://conductscience.org/library/papers/9704592 | PubMed |
| 9,285,463 | Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. | J Neurol Neurosurg Psychiatry | 1997 | https://conductscience.org/library/papers/9285463 | PubMed |
| 8,713,690 | Monoamine oxidase inhibitors. An update on drug interactions. | Drug Saf | 1996 | https://conductscience.org/library/papers/8713690 | PubMed |
| 8,390,270 | Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. | J Neural Transm Gen Sect | 1993 | https://conductscience.org/library/papers/8390270 | PubMed |
| 7,834,966 | Pharmacokinetic optimisation of therapy with newer antidepressants. | Clin Pharmacokinet | 1994 | https://conductscience.org/library/papers/7834966 | PubMed |
| 7,284,698 | Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B. | Br J Pharmacol | 1981 | https://conductscience.org/library/papers/7284698 | PubMed |
| 6,793,694 | Effects of L-deprenyl on human growth hormone secretion. | J Neural Transm | 1981 | https://conductscience.org/library/papers/6793694 | PubMed |
| 6,777,463 | Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. | J Neurol Neurosurg Psychiatry | 1980 | https://conductscience.org/library/papers/6777463 | PubMed |
| 6,776,576 | The effect of deprenyl, a selective monoamine oxidase B inhibitor, on sleep and mood in man. | Psychopharmacology (Berl) | 1980 | https://conductscience.org/library/papers/6776576 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/745014
GET https://conductscience.org/api/papers/v1/745014/cited_by?page=2